Molecular Subtypes of Prostate Cancer

Purpose of Review This review will examine the taxonomy of PCa subclasses across disease states, explore the relationship among specific alterations, and highlight current clinical relevance. Recent Findings Prostate cancer (PCa) is driven by multiple genomic alterations, with distinct patterns and...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2018-08, Vol.20 (8), p.58-9, Article 58
Main Authors: Arora, Kaveri, Barbieri, Christopher E.
Format: Article
Language:English
Subjects:
Androgen Antagonists - therapeutic use
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Disease Progression
Genitourinary Cancers (DP Petrylak and JW Kim
Humans
Male
Medicine
Medicine & Public Health
Metastases
Mutation
Neoplasm Metastasis - genetics
Oncology
Prostate cancer
Prostatic Neoplasms - classification
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Prostatic Neoplasms, Castration-Resistant - classification
Prostatic Neoplasms, Castration-Resistant - genetics
Prostatic Neoplasms, Castration-Resistant - pathology
Prostatic Neoplasms, Castration-Resistant - therapy
Receptors, Androgen - genetics
Section Editors
Taxonomy
Topical Collection on Genitourinary Cancers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review This review will examine the taxonomy of PCa subclasses across disease states, explore the relationship among specific alterations, and highlight current clinical relevance. Recent Findings Prostate cancer (PCa) is driven by multiple genomic alterations, with distinct patterns and clinical implications. Alterations occurring early in the timeline of the disease define core subtypes of localized, treatment-naive PCa. With time, an increase in number and severity of genomic alterations adds molecular complexity and is associated with progression to metastasis. These later events are not random and are influenced by the underlying subclasses. Summary All the subclasses of localized disease initially respond to androgen deprivation therapy (ADT), but with progression to castrate-resistant PCa (CRPC), mechanisms of resistance against ADT shift the molecular landscape. In CRPC, resistance mechanisms largely define the biology and sub-classification of these cancers, while clinical relevance and opportunities for precision therapy are still being defined.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-018-0707-9